Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription
Further evaluation of RF26 for the prevention or treatment of cancer and studying the role of PDE5 in tumorigenesis are warranted.
Authors
- Reem K. Fathalla
- Gang Zhou (ORCID: https://orcid.org/0000-0001-8967-114X)
- Mohammad Abdel‐Halim (ORCID: https://orcid.org/0000-0003-1326-4219)
- Yulia Maxuitenko (ORCID: https://orcid.org/0000-0001-5518-4941)
- Luciana Madeira da Silva (ORCID: https://orcid.org/0000-0002-7805-4039)
- Sara Sigler
- Matthias Engel (ORCID: https://orcid.org/0000-0001-5065-8634)
- Adam B. Keeton (ORCID: https://orcid.org/0000-0002-3053-341X)
- Gary A. Piazza (ORCID: https://orcid.org/0000-0003-4418-887X)
- Alireza Abadi (ORCID: https://orcid.org/0000-0002-7433-261X)
- Kristy Berry
Institutions
- Augusta University (US)
- USA Mitchell Cancer Institute (US)
- Auburn University (US)
- University of South Alabama (US)
- Saarland University (DE)
- German University in Cairo (EG)
Publication Details
- Journal
- Anti-Cancer Agents in Medicinal Chemistry
- Published
- 2024-09-03
- DOI
- https://doi.org/10.2174/0118715206318802240821114353
- Citations
- 3
- Primary Topic
- Phosphodiesterase function and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.70